Advertisement
U.S. markets closed
Advertisement

Precision BioSciences, Inc. (DTIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.4027-0.0023 (-0.57%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
Previous Close0.4050
Open0.4045
Bid0.3980 x 1100
Ask0.4100 x 800
Day's Range0.3936 - 0.4098
52 Week Range0.2750 - 1.4500
Volume376,093
Avg. Volume870,950
Market Cap49.097M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.8600
Earnings DateMar 07, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DTIL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Precision BioSciences, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 18,000 employees.
    Rating
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • Business Wire

    Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

    DURHAM, N.C., December 04, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled "Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease." This

  • Business Wire

    Precision BioSciences to Present at Hep-DART 2023

    DURHAM, N.C., November 30, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.

  • Business Wire

    Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., November 28, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employmen